Better Therapeutics (NASDAQ:BTTX – Get Free Report) is anticipated to release its resultson Thursday, May 14th. Analysts expect Better Therapeutics to post earnings of ($0.22) per share and revenue of $5.0430 million for the quarter.
Better Therapeutics Stock Performance
BTTX opened at $0.00 on Tuesday. Better Therapeutics has a 1 year low of $0.00 and a 1 year high of $0.00. The company has a market capitalization of $4,058.00, a P/E ratio of 0.00 and a beta of 0.87.
Better Therapeutics Company Profile
Better Therapeutics, Inc is a clinical-stage digital therapeutics company focused on developing prescription software-based treatments for cardiometabolic diseases. Its lead product candidate, BT-001, is a behavior-change program delivered via a smartphone application, designed to address underlying drivers of type 2 diabetes and hypertension through cognitive behavioral therapy techniques. The company’s platform is built to engage patients in personalized lifestyle modification, leveraging real-time feedback and data analytics to support sustained clinical improvements.
BT-001 is being evaluated in pivotal clinical trials under FDA investigational device exemptions, with studies examining its impact on glycemic control and blood pressure reduction.
Featured Articles
- Five stocks we like better than Better Therapeutics
- Before the Moon Base Gets Built, These 4 Companies Win
- Industrial Buybacks: Top Homebuilding Supplier Leads Buyback Increases
- 3 Stocks That Win If Inflation Surprises to the Downside
- MercadoLibre Boldly Invests in Growth: Discount Deepens
Receive News & Ratings for Better Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Better Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
